Denali Therapeutics Inc. Financials

Market Capitalization $2.13 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	-5.72
Forward PE	-5.34
Price to Sales TTM	$
Price to Book MRQ	$1.90
Enterprise to Revenue
Enterprise to EBITDA	-2.46

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	0.00%
Operating Margin	0.00%
Return on Assets TTM	-22.58%
Return on Equity TTM	-35.21%

Income Statement

Revenue TTM	$0
Revenue per Share TTM	$0.00
Quarterly Revenue Growth	%
Gross Profit TTM	$-395,235,008
EBITDA	$-513,951,008
Net Income to Common TTM	$-453,940,992
Diluted EPS TTM	$-2.67
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$817,926,016
Total Cash per Share MRQ	$5.63
Total Debt MRQ	$
Total Debt to Equity MRQ	4.59
Current Ratio MRQ	9.56
Book Value per Share MRQ	$7.73

Cash Flow

Operating Cash Flow TTM	$-365,542,016
Levered Free Cash Flow TTM	$-257,539,248

DNLI Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	144,220,986
Float Shares	130,572,885
Avg 10 Volume	1,722,440
Avg 30 Volume	None
Shares Short	11,947,808
Short Ratio	7.92
Short % of Shares	9.21%
% Held by Insiders	9.97%
% Held by Institutions	94.28%

Stock Price Summary

Beta	1.33
Fifty Two Week Low	$10.57
Fifty Two Week High	$33.33
Fifty Two Week Change	-43.91%
Day 50 MA	$14.50
Day 200 MA	$20.18

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date